Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty ...

Utilizing its innovative ADC payload platform, Akari is advancing a new class of immuno-oncology ADCs built on the platform of a novel PH1 payload. This payload is designed specifically to target and ...

APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 ('NK-1”) antagonist ...

Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic ...

Despite the importance of GoF modifications, they have sometimes faced misplaced concerns or opposition that could lead to their being overregulated or even banned.

MassBay Community College will hold its biannual Student STEM Expo on Wednesday, December 10, 2025, from 1:00 p.m. – 2:00 p.m. in the Wellesley Hills campus cafeteria, as well as virtually from Monday ...

Through conversations at these global forums, one insight became clear to me: Technology alone will not define the future of ...

TEHRAN- Kim Junpyo, the South Korean ambassador to Iran, said that South Korea and Iran possess unparalleled potential to ...

EVE combines evolutionary insights with human population data to identify damaging genetic mutations, improving variant ...

One of the major transformations to modern healthcare has been personalised medicine, and orthopedics has undergone this ...